Subbarayan K - Search Results

1

Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma.

Schäfer H, Subbarayan K, Massa C, Vaxevanis C, Mueller A, Seliger B. Schäfer H, et al. Among authors: subbarayan k. J Transl Med. 2023 Sep 20;21(1):643. doi: 10.1186/s12967-023-04476-x. J Transl Med. 2023. PMID: 37730606 Free PMC article.

2

Identification of a novel miR-21-3p/TGF-β signaling-driven immune escape via the MHC class I/biglycan axis in tumor cells.

Subbarayan K, Massa C, Lazaridou MF, Ulagappan K, Seliger B. Subbarayan K, et al. Clin Transl Med. 2021 Mar;11(3):e306. doi: 10.1002/ctm2.306. Clin Transl Med. 2021. PMID: 33783999 Free PMC article. No abstract available.

3

Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.

Subbarayan K, Leisz S, Wickenhauser C, Bethmann D, Massa C, Steven A, Seliger B. Subbarayan K, et al. Oncoimmunology. 2018 Jan 16;7(4):e1373233. doi: 10.1080/2162402X.2017.1373233. eCollection 2018. Oncoimmunology. 2018. PMID: 29632715 Free PMC article.

4

Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients' Outcome.

Subbarayan K, Seliger B. Subbarayan K, et al. Curr Cancer Drug Targets. 2019;19(3):210-221. doi: 10.2174/1568009618666180706165845. Curr Cancer Drug Targets. 2019. PMID: 29984655

5

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy.

Friedrich M, Jasinski-Bergner S, Lazaridou MF, Subbarayan K, Massa C, Tretbar S, Mueller A, Handke D, Biehl K, Bukur J, Donia M, Mandelboim O, Seliger B. Friedrich M, et al. Among authors: subbarayan k. Cancer Immunol Immunother. 2019 Oct;68(10):1689-1700. doi: 10.1007/s00262-019-02373-1. Epub 2019 Aug 3. Cancer Immunol Immunother. 2019. PMID: 31375885 Free PMC article. Review.

6

Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma.

Lazaridou MF, Massa C, Handke D, Mueller A, Friedrich M, Subbarayan K, Tretbar S, Dummer R, Koelblinger P, Seliger B. Lazaridou MF, et al. Among authors: subbarayan k. J Clin Med. 2020 Aug 20;9(9):2690. doi: 10.3390/jcm9092690. J Clin Med. 2020. PMID: 32825219 Free PMC article.

7

Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.

Subbarayan K, Massa C, Leisz S, Steven A, Bethmann D, Biehl K, Wickenhauser C, Seliger B. Subbarayan K, et al. Oncoimmunology. 2022 Apr 28;11(1):2069214. doi: 10.1080/2162402X.2022.2069214. eCollection 2022. Oncoimmunology. 2022. PMID: 35529675 Free PMC article.

8

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.

Vaxevanis CK, Bauer M, Subbarayan K, Friedrich M, Massa C, Biehl K, Al-Ali HK, Wickenhauser C, Seliger B. Vaxevanis CK, et al. Among authors: subbarayan k. Oncoimmunology. 2022 Dec 15;12(1):2152998. doi: 10.1080/2162402X.2022.2152998. eCollection 2023. Oncoimmunology. 2022. PMID: 36531688 Free PMC article.

9

Expression and Clinical Significance of SARS-CoV-2 Human Targets in Neoplastic and Non-Neoplastic Lung Tissues.

Subbarayan K, Ulagappan K, Wickenhauser C, Seliger B. Subbarayan K, et al. Curr Cancer Drug Targets. 2021 Jul 5;21(5):428-442. doi: 10.2174/1568009620666201207145019. Curr Cancer Drug Targets. 2021. PMID: 33292131

10

Immune Interaction Map of Human SARS-CoV-2 Target Genes: Implications for Therapeutic Avenues.

Subbarayan K, Ulagappan K, Wickenhauser C, Bachmann M, Seliger B. Subbarayan K, et al. Front Immunol. 2021 Mar 16;12:597399. doi: 10.3389/fimmu.2021.597399. eCollection 2021. Front Immunol. 2021. PMID: 33796097 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters